Raymond James resumed coverage of Jazz Pharmaceuticals (JAZZ) with an Outperform rating and $227 price target The Jazz story has moved beyond the “it looks inexpensive/fairly valued, but where can I get upside?” narrative since adding greater visibility to the tail value of the Epidiolex franchise and zanidatamab delivering “highly competitive” data in gastroesophageal adenocarcinoma, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals price target raised to $232 from $219 at Piper Sandler
- Jazz Pharmaceuticals to present clinical, preclinical data at AACR 2026
- Zymework’ partner Jazz to present on Ziihera at 2026 AACR Annual Meeting
- 3 Best Value Stocks with Over 10% Upside in 2026, According to Analysts
- Jazz Pharmaceuticals price target raised to $226 from $225 at Deutsche Bank